Systemic Hydrocortisone To Prevent Bronchopulmonary Dysplasia in preterm infants (the SToP-BPD study): statistical...

Area of Science:

• Neonatal Medicine
• Pediatric Pulmonology
• Clinical Trials

Background:

• Bronchopulmonary dysplasia (BPD) is a common, serious complication of preterm birth.
• Dexamethasone prevents BPD but carries neurodevelopmental risks.
• Hydrocortisone is being explored as a safer alternative for BPD prevention.

Purpose of the Study:

• To evaluate the efficacy and safety of postnatal hydrocortisone for preventing BPD in ventilator-dependent preterm infants.
• To assess hydrocortisone's impact on the composite outcome of death or BPD at 36 weeks postmenstrual age.
• To examine short-term pulmonary effects and long-term neurodevelopmental sequelae.

Main Methods:

• A multicenter, double-blind, placebo-controlled trial (SToP-BPD) involving preterm infants at risk for BPD.
• Infants were randomly assigned to a 22-day treatment of hydrocortisone or placebo.
• Primary outcome: composite of death or BPD at 36 weeks PMA; Secondary outcomes: pulmonary status and neurodevelopment at 2 years corrected age.

Main Results:

• The primary outcome measure is the composite outcome of death or BPD at 36 weeks postmenstrual age.
• Secondary outcomes include short-term pulmonary condition and long-term neurodevelopmental sequelae.
• Safety outcomes involve treatment complications and adverse events.

Conclusions:

• The study aims to determine if hydrocortisone is an effective and safe alternative to dexamethasone for BPD prevention.
• Findings will inform clinical practice regarding the management of ventilator-dependent preterm infants at risk for BPD.
• The trial will provide crucial data on the long-term neurodevelopmental effects of hydrocortisone therapy.